BI 770371 + pembrolizumab + cetuximab

BI 770371 + pembrolizumab + cetuximab is a **combination therapy** investigated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). **Pembrolizumab** is a monoclonal antibody and programmed cell death protein 1 (PD-1) inhibitor that enhances anti-tumor immunity by enabling cytotoxic T lymphocytes to target tumor cells[1][3][4]. **Cetuximab** is a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), thus blocking tumor cell proliferation and inducing antibody-dependent cellular cytotoxicity[1][3][4]. BI 770371 is a Boehringer Ingelheim investigational compound, but no direct clinical data combining it specifically with pembrolizumab and cetuximab in the published literature or registered trials was found as of the current cutoff date. The described combination utilizes mechanistically distinct immunotherapies and a targeted agent, aiming for synergistic anti-tumor effects, particularly in platinum-resistant or platinum-ineligible HNSCC[1][3][4].

Other names

pembrolizumabcetuximab